<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="873">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04841135</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL19_0041</org_study_id>
    <nct_id>NCT04841135</nct_id>
  </id_info>
  <brief_title>Blood Microbiota Signature of Alzheimer's Disease</brief_title>
  <acronym>MICMALZ</acronym>
  <official_title>Analysis of the Blood Signature of the Microbiota as a Diagnostic Marker of Alzheimer's Disease in the Early Stages of the Process: Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to validate a difference in blood microbial signature between Alzheimer's&#xD;
      patients and control subjects in order to propose potential innovative strategies&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study only carried out in Montpellier, aimed at comparing AD patients with&#xD;
      control subjects, including men / women aged between 50 and 85 years. The diagnosis of AD&#xD;
      patients is based on international criteria. Metagenomics and proteomics will be used to&#xD;
      determine the composition of the microbiota in whole blood and stools, but also the&#xD;
      metabolomic profile in plasma, stool and the urines.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of bacterial 16S rDNA in stools</measure>
    <time_frame>22 months</time_frame>
    <description>Concentration of bacterial 16S rDNA in stools</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Concentration of bacterial 16s DNA in blood</measure>
    <time_frame>22 months</time_frame>
    <description>Concentration of bacterial 16s DNA in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiomics microbiota signature in AD</measure>
    <time_frame>22 months</time_frame>
    <description>Multiomics microbiota signature in AD</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Elderly With Normal Cognition</condition>
  <arm_group>
    <arm_group_label>Alzheimer disease group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Multiomics quantification</intervention_name>
    <description>One time blood, stool and urine samples will be taken.</description>
    <arm_group_label>Alzheimer disease group</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        General criteria:&#xD;
&#xD;
          -  Male and/or female;&#xD;
&#xD;
          -  Age between 50-85 years;&#xD;
&#xD;
          -  Having given their free, informed, written consent, signed by the participant and the&#xD;
             investigator (at the latest on the day of inclusion and before any examination&#xD;
             required by the research);&#xD;
&#xD;
          -  Patient benefiting from a social security scheme&#xD;
&#xD;
        AD group:&#xD;
&#xD;
          -  Diagnosis of Alzheimer's disease according to the international ATN criteria of Albert&#xD;
             et al, (1) who had a diagnostic lumbar puncture and CSF biomarker assay and brain&#xD;
             imaging with analysis of hippocampal atrophy; topographic and pathophysiological&#xD;
             markers must be positive to confirm the etiopathogenic diagnosis;&#xD;
&#xD;
          -  Mild to moderate stage with MMSE score between 10 and 26 ;&#xD;
&#xD;
          -  Symptomatic treatments specific to Alzheimer's disease (acetylcholinesterase&#xD;
             inhibitors and memantine) and psychotropic treatments (anxiolytics, antidepressants,&#xD;
             neuroleptics) are authorized but must be at fixed doses for more than 3 months ;&#xD;
&#xD;
        Control group:&#xD;
&#xD;
        - Patients seen in memory consultation for concern of having AD but for whom the workup is&#xD;
        normal. These patients will have had a diagnostic lumbar puncture during the same memory&#xD;
        consultation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
        General criteria:&#xD;
&#xD;
          -  Male and/or female;&#xD;
&#xD;
          -  Age between 50-85 years;&#xD;
&#xD;
          -  Having given their free, informed, written consent, signed by the participant and the&#xD;
             investigator (at the latest on the day of inclusion and before any examination&#xD;
             required by the research);&#xD;
&#xD;
          -  Patient benefiting from a social security scheme&#xD;
&#xD;
        AD group:&#xD;
&#xD;
          -  Diagnosis of Alzheimer's disease according to the international ATN criteria of Albert&#xD;
             et al, (1) who had a diagnostic lumbar puncture and CSF biomarker assay and brain&#xD;
             imaging with analysis of hippocampal atrophy; topographic and pathophysiological&#xD;
             markers must be positive to confirm the etiopathogenic diagnosis;&#xD;
&#xD;
          -  Mild to moderate stage with MMSE score between 10 and 26 ;&#xD;
&#xD;
          -  Symptomatic treatments specific to Alzheimer's disease (acetylcholinesterase&#xD;
             inhibitors and memantine) and psychotropic treatments (anxiolytics, antidepressants,&#xD;
             neuroleptics) are authorized but must be at fixed doses for more than 3 months ;&#xD;
&#xD;
        Control group:&#xD;
&#xD;
        - Patients seen in memory consultation for concern of having AD but for whom the workup is&#xD;
        normal. These patients will have had a diagnostic lumbar puncture during the same memory&#xD;
        consultation.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        General criteria:&#xD;
&#xD;
          -  Absence of a family caregiver to complete the neuropsychological scales and&#xD;
             questionnaires ;&#xD;
&#xD;
          -  Patient living in a medical institution;&#xD;
&#xD;
          -  Illiteracy or inability to complete the psycho-behavioral tests;&#xD;
&#xD;
          -  Major physical or neurosensory problems likely to interfere with the tests;&#xD;
&#xD;
          -  Contra-indication or refusal to perform the biological tests;&#xD;
&#xD;
          -  Refusal to carry out neuropsychological tests.&#xD;
&#xD;
          -  Refusal of stool collection&#xD;
&#xD;
          -  Digestive neoplasia in progress or &lt; 5 years old&#xD;
&#xD;
          -  Digestive surgery with intestinal resection ;&#xD;
&#xD;
          -  Presence of inflammatory bowel disease or other familial gastrointestinal pathology ;&#xD;
&#xD;
          -  Chronic use of laxatives;&#xD;
&#xD;
          -  Antibiotics taken within one month prior to inclusion;&#xD;
&#xD;
          -  Short-term life-threatening conditions (active cancer, unstable heart failure, severe&#xD;
             liver, kidney and respiratory failure);&#xD;
&#xD;
          -  Chronic psychosis or psychotic episodes;&#xD;
&#xD;
          -  Alcohol or drug addiction;&#xD;
&#xD;
          -  Epilepsy and other non-degenerative diseases of the central nervous system&#xD;
&#xD;
          -  Vitamin B12 deficiency and unsupplemented folic acid ;&#xD;
&#xD;
          -  Untreated hypothyroidism;&#xD;
&#xD;
          -  Patient deprived of liberty, by judicial or administrative decision;&#xD;
&#xD;
          -  Major protected by law;&#xD;
&#xD;
          -  Patient in a period of relative exclusion from another protocol;&#xD;
&#xD;
          -  Refusal to participate in the protocol.&#xD;
&#xD;
        AD group :&#xD;
&#xD;
          -  Insufficient clinical and paraclinical information for the diagnosis of AD;&#xD;
&#xD;
          -  Genetic form of AD (known genetic mutation);&#xD;
&#xD;
        Control group: No specific non-inclusion criteria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Audrey GABELLE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montpellier University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Audrey GABELLE, MD, PhD</last_name>
    <phone>+33 4 67 33 60 29</phone>
    <email>a-gabelle@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sylvie CLAEYSEN</last_name>
    <phone>+33 4 34 35 92 15</phone>
    <email>sylvie.claeysen@igf.cnrs.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montpellier university hospital</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey GABELLE, MD, PhD</last_name>
      <phone>+33 4 67 33 60 29</phone>
      <email>a-gabelle@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sylvie CLAEYSEN</last_name>
      <phone>+33 4 34 35 92 15</phone>
      <email>sylvie.claeysen@igf.cnrs.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer</keyword>
  <keyword>Memory</keyword>
  <keyword>Aging</keyword>
  <keyword>Microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

